LU86919A1 - Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b. - Google Patents

Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b. Download PDF

Info

Publication number
LU86919A1
LU86919A1 LU86919A LU86919A LU86919A1 LU 86919 A1 LU86919 A1 LU 86919A1 LU 86919 A LU86919 A LU 86919A LU 86919 A LU86919 A LU 86919A LU 86919 A1 LU86919 A1 LU 86919A1
Authority
LU
Luxembourg
Prior art keywords
cells
lymphocytes
fab
compound
coordinate
Prior art date
Application number
LU86919A
Other languages
English (en)
French (fr)
Inventor
Edward A Clark
Jeffrey A Ledeetter
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of LU86919A1 publication Critical patent/LU86919A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LU86919A 1986-06-13 1987-06-12 Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b. LU86919A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87388486A 1986-06-13 1986-06-13
US87388486 1986-06-13

Publications (1)

Publication Number Publication Date
LU86919A1 true LU86919A1 (fr) 1989-03-08

Family

ID=25362524

Family Applications (1)

Application Number Title Priority Date Filing Date
LU86919A LU86919A1 (fr) 1986-06-13 1987-06-12 Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b.

Country Status (22)

Country Link
JP (1) JPH0762040B2 (de)
KR (1) KR910004100B1 (de)
AT (1) AT398437B (de)
AU (1) AU617087B2 (de)
BE (1) BE1000587A4 (de)
CA (1) CA1338781C (de)
CH (1) CH676600A5 (de)
CY (1) CY1681A (de)
DE (1) DE3719398C2 (de)
DK (1) DK173940B1 (de)
FR (1) FR2607136B1 (de)
GB (1) GB2191494B (de)
GR (1) GR870930B (de)
HK (1) HK10293A (de)
IE (1) IE60486B1 (de)
IL (1) IL82841A (de)
IT (1) IT1208649B (de)
LU (1) LU86919A1 (de)
NL (1) NL195022C (de)
PT (1) PT85073B (de)
SE (1) SE504675C2 (de)
SG (1) SG118992G (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
EP0117705A3 (de) * 1983-02-24 1985-09-25 The Regents Of The University Of California Monocyten und Blastzellen spezifischer monoklonaler Antikörper
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof

Also Published As

Publication number Publication date
IL82841A0 (en) 1987-12-20
CA1338781C (en) 1996-12-10
SE8702463L (sv) 1987-12-14
CH676600A5 (de) 1991-02-15
DK302287D0 (da) 1987-06-12
IT8720899A0 (it) 1987-06-12
SE8702463D0 (sv) 1987-06-12
GB8713650D0 (en) 1987-07-15
HK10293A (en) 1993-02-19
SE504675C2 (sv) 1997-04-07
PT85073A (en) 1987-07-01
CY1681A (en) 1993-10-10
DK173940B1 (da) 2002-03-04
IT1208649B (it) 1989-07-10
AU7421487A (en) 1987-12-17
DK302287A (da) 1987-12-14
FR2607136B1 (fr) 1989-09-15
JPS6480299A (en) 1989-03-27
AU617087B2 (en) 1991-11-21
GB2191494A (en) 1987-12-16
IE60486B1 (en) 1994-07-27
NL195022C (nl) 2003-06-18
PT85073B (pt) 1990-07-31
ATA151387A (de) 1994-04-15
DE3719398C2 (de) 1996-03-28
SG118992G (en) 1993-01-29
IE871563L (en) 1987-12-13
AT398437B (de) 1994-12-27
KR880000582A (ko) 1988-03-28
IL82841A (en) 1992-11-15
DE3719398A1 (de) 1988-01-28
FR2607136A1 (fr) 1988-05-27
JPH0762040B2 (ja) 1995-07-05
NL8701371A (nl) 1988-01-04
KR910004100B1 (ko) 1991-06-22
GB2191494B (en) 1990-08-22
GR870930B (en) 1987-12-16
BE1000587A4 (fr) 1989-02-14

Similar Documents

Publication Publication Date Title
US5182368A (en) Ligands and methods for augmenting B-cell proliferation
JP3611573B2 (ja) モノクローナル抗体の免疫抑制活性および毒性のモジュレーションのための方法ならびに物質
US5786456A (en) Bp 50-specific antibodies and fragments thereof
Scholl et al. Toxic shock syndrome toxin 1 binds to major histocompatibility complex class II molecules.
AU605516B2 (en) Ex vivo effector cell activation for target cell killing
EP0626447B1 (de) Monoklonale Antikörper und Fv gegen das CD2 Antigen
JP3095175B2 (ja) Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
FI75183C (fi) Foerfarande foer framstaellning av en komplement-bindande monoklonal antikropp mot maenniskans t-celler genom anvaendning av en ny hybridcellinje.
Knox et al. Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides
FI105320B (fi) Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
US6197298B1 (en) Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
TW202043263A (zh) Ｇｐｒｃ５ｄ嵌合抗原受體及表現其之細胞
JPH05268986A (ja) モノクローナル抗体及びリンパ球の活性法
EP0504327B1 (de) Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon
JPH07126300A (ja) ヒトのｂ細胞受容体複合体の特異抗原を認識するモノクローナル抗体
RO114980B1 (ro) Molecula anticorp capabila sa se lege la antigena cd4, secventa de nucleotide, procedeu de preparare si metoda de tratament
Bazin et al. Rat hybridomas and rat monoclonal antibodies
WO1996014865A1 (en) Methods for inhibiting graft versus host disease in bone marrow transplantation
Klingbeil et al. Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use
BE1000587A4 (fr) Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b.
KR102693802B1 (ko) 변형된 이식편의 사전 사용에 의한 이식편 거부의 방지
WO1991012332A1 (fr) Anticorps monoclonaux reconnaissant un peptide associe a un antigene majeur d'histocompatibilite
JP2023523682A (ja) Ｂ細胞急性リンパ芽球性白血病（ｂ－ａｌｌ）の処置のためのｃｄ２２標的化部分
Maruoka et al. A novel monoclonal antibody permitting recognition of NKT cells in various mouse strains
CA1270778A (fr) Cellules hybrides secretant des anticorps anti- idiotypiques, anticorps monoclonaux secretes par lesdites cellules hybrides, leur preparation et leur application

Legal Events

Date Code Title Description
DT Application date
TA Annual fee